Grigoropoulos Ioannis, Thomas Konstantinos, Christoforou Panagiotis, Fanidi Iliana, Papavdi Maria, Kyriakou Fani, Deutsch Melanie, Pirounaki Maria, Vassilopoulos Dimitrios
2 Department of Medicine and Laboratory, National and Kapodistrian University of Athens Medical School, Hippokration General Hospital, Athens, Greece.
Mediterr J Rheumatol. 2019 Sep 30;30(3):167-170. doi: 10.31138/mjr.30.3.167. eCollection 2019 Sep.
The use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) in rheumatic diseases is constantly increasing during the last decade. Tofacitinib is a new oral Janus Kinase (JAK) inhibitor, approved for rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colitis. Safety data of tofacitinib derived from randomized controlled trials and long-term extension studies has demonstrated a moderate increase in the risk for common serious infections. We describe a case of pneumonia (PJP) in a woman on tofacitinib therapy for RA. Although tofacitinib use has been associated with the development of opportunistic infections, PJP has been rarely reported. PJP should be included in the differential diagnosis of patients with autoimmune disorders under newer oral JAK inhibitors therapy who present with fever, hypoxia and pulmonary infiltrates.
在过去十年中，生物制剂和靶向合成改善病情抗风湿药（tsDMARDs）在风湿性疾病中的使用一直在不断增加。托法替布是一种新型口服 Janus 激酶（JAK）抑制剂，已被批准用于治疗类风湿关节炎（RA）、银屑病关节炎和溃疡性结肠炎。来自随机对照试验和长期扩展研究的托法替布安全性数据表明，常见严重感染风险有适度增加。我们描述了一名接受托法替布治疗 RA 的女性发生肺孢子菌肺炎（PJP）的病例。尽管使用托法替布与机会性感染的发生有关，但 PJP 的报道很少。对于接受新型口服 JAK 抑制剂治疗且出现发热、缺氧和肺部浸润的自身免疫性疾病患者，应将 PJP 纳入鉴别诊断。
